Home » Posts tagged with » Johnson & Johnson (Page 2)
FDA approves IMBRUVICA, rituximab combo for rare blood cancer

Janssen Pharmaceutical has bagged approval from the US Food and Drug Administration (FDA) for its combo of IMBRUVICA (ibrutinib) and rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer. The FDA approval secured by the Johnson & Johnson subsidiary expands IMBRUVICA’s current label in Waldenström’s macroglobulinemia as a monotherapy to include its […]

Continue reading …
Page 2 of 212